dc.contributor.author | Livi, L | |
dc.contributor.author | Shah, N | |
dc.contributor.author | Paiar, F | |
dc.contributor.author | Fisher, C | |
dc.contributor.author | Judson, I | |
dc.contributor.author | Moskovic, E | |
dc.contributor.author | Thomas, M | |
dc.contributor.author | Harmer, C | |
dc.date.accessioned | 2018-06-26T08:38:15Z | |
dc.date.issued | 2003-01-01 | |
dc.identifier | http://publications.icr.ac.uk/1231/ | |
dc.identifier.citation | SARCOMA, 2003, 7 (3?4), pp. 149 - 152 | |
dc.identifier.issn | 1357-714X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1923 | |
dc.description.abstract | <jats:p><jats:italic>Purpose:</jats:italic> The aim of this study was to assess treatment and outcome with respect to clinical and pathological features.</jats:p><jats:p><jats:italic>Patients and methods:</jats:italic> Thirty‐nine patients were identified (range 7–66 years, mean 23). Initial treatment comprised local
excision in 11 patients and wide excision in 14. Post‐operative external beam radiotherapy was prescribed in 22 patients
with a total dose of 60 Gy, delivered in two phases.</jats:p><jats:p><jats:italic>Results:</jats:italic> The cause‐specific survival for the entire group was 79, 63, 56 and 45% at 1, 3, 5 and 10 years, respectively. A distal
limb location was associated with a better prognosis than proximal limb location (<jats:italic>P</jats:italic> = 0.04).</jats:p><jats:p><jats:italic>Conclusions:</jats:italic> Our data favour treatment with wide functional excision followed by radical dose radiotherapy in attempt to
minimize risk of local recurrence, especially when primary tumours are bigger than 3 cm. Our data also suggest the same
treatment for local recurrence, when technically possible, to avoid amputation.</jats:p> | |
dc.format.extent | 149 - 152 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Wiley | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Treatment of Epithelioid Sarcoma at the Royal Marsden Hospital | |
dc.type | Journal Article | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2003 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | SARCOMA | |
pubs.issue | 3?4 | |
pubs.notes | public | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials | |
pubs.volume | 7 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Sarcoma Clinical Trials | |
dc.contributor.icrauthor | Judson, Ian | |